Prognostic risk factors of serous ovarian carcinoma based on mesenchymal stem cell phenotype and guidance for therapeutic efficacy.

Yang, Xiaohui; Zheng, Minying; Ning, Yidi; Sun, Jie; Yu, Yongjun; Zhang, Shiwu

Yang, Xiaohui; Zheng, Minying; Ning, Yidi; Sun, Jie; Yu, Yongjun; Zhang, Shiwu.

Afiliação

Yang X; Nankai University School of Medicine, Nankai University, Tianjin, 300071, People's Republic of China.
Zheng M; Department of Pathology, Tianjin Union Medical Center, Tianjin, 300121, People's Republic of China.
Ning Y; Nankai University School of Medicine, Nankai University, Tianjin, 300071, People's Republic of China.
Sun J; Nankai University School of Medicine, Nankai University, Tianjin, 300071, People's Republic of China.
Yu Y; Nankai University School of Medicine, Nankai University, Tianjin, 300071, People's Republic of China.
Zhang S; Department of Pathology, Tianjin Union Medical Center, Tianjin, 300121, People's Republic of China. zhangshiwu666@aliyun.com.

J Transl Med ; 21(1): 456, 2023 07 11.

Article em En | MEDLINE | ID: mdl-37434173

Assuntos

Cistadenocarcinoma Seroso; Metaloproteinase 17 da Matriz; Neoplasias Ovarianas; Humanos; Feminino; Prognóstico; Carcinoma Epitelial do Ovário; Neoplasias Ovarianas/genética; Neoplasias Ovarianas/terapia

Palavras-chave

Immunochemistry; Mesenchymal stem cell; Metastasis; Prognosis model; Serous ovarian carcinoma

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Etiology_studies / Guideline / Prognostic_studies / Risk_factors_studies Limite: Female / Humans Idioma: En Ano de publicação: 2023 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google